REGENXBIO Inc. filed a current report on August 24, 2026, disclosing that the U.S. Food and Drug Administration placed the company's Investigational New Drug application for its Phase I/II/III trial of RGX-121 on clinical hold, and that the company does not expect to resubmit the RGX-121 Biologics License Application in the near term.
Key Highlights
- Clinical hold imposed: The FDA communicated to REGENXBIO that the Investigational New Drug application for the Phase I/II/III trial of RGX-121 was placed on clinical hold.
- Indication targeted: RGX-121 is being studied for Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome.
- BLA resubmission delayed: According to the filing, the company does not expect to resubmit the RGX-121 Biologics License Application in the near term.
- Disclosure date: The announcement was made on August 24, 2026, the date of the earliest event reported.
- Signed by: The report was signed by Patrick J. Christmas II, Executive Vice President, Chief Strategy and Legal Officer.
REGENXBIO Discloses FDA Clinical Hold on RGX-121 IND and BLA Timeline Update
According to the filing, REGENXBIO Inc. (NASDAQ:RGNX) received communication from the U.S. Food and Drug Administration indicating that the company's Investigational New Drug application covering its Phase I/II/III clinical trial of RGX-121 has been placed on clinical hold. The filing identifies RGX-121 as a therapy being developed for Mucopolysaccharidosis type II, a condition also referred to in the filing as Hunter Syndrome.
The company disclosed the development under both Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events) of the current report. In both items, the filing states that the company "does not expect to resubmit the RGX-121 Biologics License Application in the near term." No specific timeline for a potential future resubmission was provided in the filing, and no additional details about the basis for the FDA's clinical hold were included in the current report text itself.
The filing notes that the information furnished under Item 7.01 and the accompanying Exhibit 99.1 press release "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934." A press release dated August 24, 2026 was attached as Exhibit 99.1. The cover page of the current report was also filed in Inline XBRL format as Exhibit 104. REGENXBIO is incorporated in Delaware and headquartered at 9804 Medical Center Drive, Rockville, Maryland 20850.
What Was Disclosed
REGENXBIO disclosed on August 24, 2026 that the FDA placed its RGX-121 Investigational New Drug application on clinical hold and that the company does not expect to resubmit the related Biologics License Application in the near term.




Please wait processing your request...